Search

Author/Creator Ponce, L

1. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Issue 6 (19th December 2016)

Authors:
Kavanaugh, A; Kremer, J; Ponce, L; Cseuz, R; Reshetko, O V; Stanislavchuk, M; Greenwald, M; Van der Aa, A; Vanhoutte, F; Tasset, C; Harrison, P
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 6(2017)
Page Start:
1009
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks. (15th June 2017)

Authors:
Alten, R; Westhovens, R; Kavanaugh, A; Genovese, M; Winthrop, K; Greenwald, M; Ponce, L; Enriquez, F; Stanislavchuk, M; Mazur, M; Spindler, A; Cseuz, R; Nikulenkova, N; Glowacka-Kulesz, M; Szombati, I; Dudek, A; Meuleners, L; Tasset, C; Harrison, P; Aa, A Van der
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
267
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗